Screening Libraries

Inhibitors

Product Data Sheet

2,4,6-Triiodophenol

Cat. No.: HY-W073687 CAS No.: 609-23-4 Molecular Formula: $C_6H_3I_3O$


Molecular Weight: 471.8

Target: **Apoptosis** Pathway: **Apoptosis**

Storage: 4°C, protect from light, stored under nitrogen

* In solvent: -80°C, 6 months; -20°C, 1 month (protect from light, stored under

nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO: 250 mg/mL (529.89 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.1195 mL	10.5977 mL	21.1954 mL
	5 mM	0.4239 mL	2.1195 mL	4.2391 mL
	10 mM	0.2120 mL	1.0598 mL	2.1195 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description 2,4,6-Triiodophenol is an orally active and potent leukotriene B₄ (LTB₄) synthesis inhibitor. 2,4,6-Triiodophenol can induce

mouse blastocysts apoptosis [1][2].

In Vitro 2,4,6-Triiodophenol (5-50 μM; 0-100 h) impairs the quality of pre-implantation mouse embryos in a dose-dependent manner, inducing decline of both total and trophectoderm cell numbers $\[2\]$.

2,4,6-Triiodophenol (5 μ M; 85 h) shows increasement of apoptotic cells in mouse pre-implantation embryos $^{[2]}$.

2,4,6-Triiodophenol (5-50 µM; 100 h) induces oxidative stress in mouse pre-implantation embryos^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[2]

Cell Line:	Mouse blastocyst cells	
Concentration:	5 μΜ	
Incubation Time:	85 hours	
Result:	Showed signals of activated Caspase-3/7.	

Immunofluorescence ^[2]	
Cell Line:	Mouse blastocyst cells
Concentration:	5-50 μΜ
Incubation Time:	100 hours
Result:	Resulted in marked increase of oxygen species (ROS) treated with high dose of 2,4,6- Triiodophenol.

REFERENCES

[1]. Liu S, et al. 2,4,6-triiodophenol exhibits embryotoxicity to pre-implantation mouse embryos in an in vitro exposure model. Ecotoxicol Environ Saf. 2022 Aug;241:113745.

[2]. Trocóniz IF, et al. Dealing with time-dependent pharmacokinetics during the early clinical development of a new leukotriene B4 synthesis inhibitor. Pharm Res. 2006 Jul;23(7):1533-42.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech @ Med Chem Express.com$

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA